Achieve Life Sciences Announcement
Wednesday, April 22, 2026
Posted by: Natalia Gromov
Achieve Life Sciences recently provided a business update on cytisinicline, highlighting several milestones relevant to the tobacco treatment community. The company’s new drug application (NDA) for cytisinicline was accepted by the FDA last September, with a target action date of June 20, 2026, which will determine whether the medication is approved for smoking cessation. Achieve also noted that it has a commercial manufacturing agreement in place and is preparing for launch, with expectations that cytisinicline could be available in the U.S. in the first half of 2027, if approved. This would represent the first new FDA-approved pharmacotherapy for smoking cessation in nearly 20 years! The company is also continuing development toward a potential indication for vaping cessation. For programs and providers, the June 2026 decision is the key near-term milestone. With possible market availability to follow in 2027, states, quitlines, and health systems should begin to consider how a new medication could be integrated into treatment services.
Learn more.
|
|
Email to a Friend